PMID- 28256068
OWN - NLM
STAT- MEDLINE
DCOM- 20180129
LR  - 20210109
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 6
IP  - 5
DP  - 2017 May
TI  - Correlation between Trop2 and amphiregulin coexpression and overall survival in 
      gastric cancer.
PG  - 994-1001
LID - 10.1002/cam4.1018 [doi]
AB  - Gastric cancer (GC) is a multistep and multistage disease and the majority of GC 
      cells could overexpressed one or more oncogenes. Trop2 and amphiregulin (AREG) 
      are both overexpressed in various epithelial cell cancers and have the role in 
      the increases tumor cells division and metastasis. However, little is known about 
      the function and correlation of two oncogenes coexpressed in GC. The expression 
      level of these two genes in 791 cases of GC tissues were tested, the correlations 
      between two genes expression and clinical pathological characteristics and 
      overall survival in GC patients through immunohistochemistry (IHC) were analyzed. 
      This study also explored the mRNA expression level of two genes in 26 cases of 
      freshly GC tissues by qRT-PCR. The results indicated that Trop2+/AREG+ 
      coexpression was higher in GC tissues than in adjacent tissues. Trop2+/AREG+ 
      protein coexpression were associated with Tumor Node Metastasis (TNM) stage (chi(2) 
       = 50.345, P < 0.001), tumor size (chi(2)  = 40.349, P < 0.001), lymph node 
      metastases (chi(2)  = 26.481, P < 0.001), and distant metastases (chi(2)  = 8.387, 
      P = 0.039). GC patients with Trop2+ and AREG+ protein coexpression had poor 
      overall survival rates (HR = 3.682, 95% CI = 2.038-6.654, P < 0.001). The 
      expression level of Trop2/AREG were positively correlated (r 0.254 and 
      P < 0.001). The result of the mRNA expression was similar to that of the protein 
      expression. Overall, Trop2 and AREG could be seen as prognostic cobiomarker in GC 
      and combined detection of Trop2 and AREG could be viewed as helpful in predicting 
      the prognosis of the GC patients.
CI  - (c) 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Zhao, Wei
AU  - Zhao W
AUID- ORCID: 0000-0001-8557-297X
AD  - Department of Pathology, Nanjing Medical University, Nanjing, 210029, China.
AD  - School of Public Health, Nantong University, Nantong, 226019, China.
FAU - Ding, Guipeng
AU  - Ding G
AD  - Department of Pathology, Nanjing Medical University, Nanjing, 210029, China.
FAU - Wen, Jinbo
AU  - Wen J
AD  - Department of Epidemiology, School of Public Health, Nanjing Medical University, 
      Nanjing, 210029, China.
FAU - Tang, Qi
AU  - Tang Q
AD  - Key Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical 
      University, Nanjing, 210029, China.
FAU - Yong, Hongmei
AU  - Yong H
AD  - Department of Oncology, Huai'an Hospital Affiliated of Xuzhou Medical College and 
      Huai'an Second People's Hospital, Huai'an, 223001, China.
FAU - Zhu, Huijun
AU  - Zhu H
AD  - Department of Pathology, Affiliated Hospital of Nantong University, Nantong, 
      226019, China.
FAU - Zhang, Shu
AU  - Zhang S
AD  - Department of Pathology, Affiliated Hospital of Nantong University, Nantong, 
      226019, China.
FAU - Qiu, Zhenning
AU  - Qiu Z
AD  - Key Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical 
      University, Nanjing, 210029, China.
FAU - Feng, Zhenqing
AU  - Feng Z
AD  - Department of Pathology, Nanjing Medical University, Nanjing, 210029, China.
AD  - Key Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical 
      University, Nanjing, 210029, China.
AD  - Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 
      Medical University, Nanjing, 210029, China.
AD  - Key Laboratory of Cancer Biomarkers, Prevent and Treatment, Cancer Center, 
      Nanjing Medical University, Nanjing, 210029, China.
FAU - Zhu, Jin
AU  - Zhu J
AD  - Key Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical 
      University, Nanjing, 210029, China.
AD  - Huadong Medical Institute of Biotechniques, Nanjing, 210029, China.
LA  - eng
PT  - Journal Article
DEP - 20170303
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (AREG protein, human)
RN  - 0 (Amphiregulin)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (TACSTD2 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amphiregulin/*genetics/*metabolism
MH  - Antigens, Neoplasm/*genetics/*metabolism
MH  - Cell Adhesion Molecules/*genetics/*metabolism
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Stomach Neoplasms/genetics/metabolism/*pathology
MH  - Survival Analysis
MH  - *Up-Regulation
PMC - PMC5430091
OTO - NOTNLM
OT  - AREG
OT  - Trop2
OT  - coexpression
OT  - correlation
OT  - gastric cancer
EDAT- 2017/03/04 06:00
MHDA- 2018/01/30 06:00
PMCR- 2017/03/03
CRDT- 2017/03/04 06:00
PHST- 2016/09/28 00:00 [received]
PHST- 2016/11/14 00:00 [revised]
PHST- 2016/12/27 00:00 [accepted]
PHST- 2017/03/04 06:00 [pubmed]
PHST- 2018/01/30 06:00 [medline]
PHST- 2017/03/04 06:00 [entrez]
PHST- 2017/03/03 00:00 [pmc-release]
AID - CAM41018 [pii]
AID - 10.1002/cam4.1018 [doi]
PST - ppublish
SO  - Cancer Med. 2017 May;6(5):994-1001. doi: 10.1002/cam4.1018. Epub 2017 Mar 3.